Marpai, INC

Marpai, Inc. has announced the closing of a private placement, raising approximately $12.1 million through the sale of Series A Convertible Preferred Stock to accredited investors.

Marpai, Inc. announced debt restructuring agreements with JGB Capital and AXA S.A., reducing debt service by $26.4 million through 2027 and enhancing near-term liquidity.

Marpai, Inc. announced that CEO Damien Lamendola will assume the role of President following Dallas Scrip's resignation, effective January 30, 2026.

Marpai Inc. announced a private placement of common stock and warrants, raising approximately $350,000 for working capital and general corporate purposes.

Marpai, Inc. reports significant operational and financial improvements in Q3 2025, driven by cost discipline and strategic capital infusion, positioning for 2026 growth.

Marpai Inc. announced a private placement raising approximately $4 million through the issuance of common stock and warrants, with significant participation from company insiders.

Marpai, Inc. reported a significant revenue decline and continued net losses for Q3 2025, raising substantial doubt about its ability to continue as a going concern, while actively pursuing strategic alternatives and capital raises.

Marpai, Inc. reports a significant reduction in net loss for Q2 2025, but faces substantial doubt about its ability to continue as a going concern due to declining revenue and negative working capital.

Marpai Inc. reports a decrease in revenue for Q1 2025, alongside an ongoing strategic review to maximize shareholder value and address liquidity concerns.

Marpai Inc. reported a decrease in revenue for the third quarter of 2024, alongside a net loss, while also announcing a strategic review to maximize shareholder value.

Marpai Inc.'s Q2 2024 results reveal a significant net loss, revenue decline, and a going concern warning, alongside a transition to the OTCQX market.

Marpai Inc. reported a net loss of $4.3 million for the first quarter of 2024, alongside a decrease in revenue and ongoing concerns about its ability to continue as a going concern.

Marpai Inc. reported a significant revenue decline and ongoing operating losses for 2025, leading to substantial doubt about its ability to continue as a going concern, despite strategic restructuring efforts.

Marpai Inc.'s 2024 annual report reveals a net loss, revenue decline, and an auditor's note raising substantial doubt about the company's ability to continue as a going concern.

Marpai Inc.'s annual 10-K filing provides a comprehensive overview of its business, financial condition, and risk factors, highlighting its technology-driven healthcare administration services.

Marpai, Inc. Director Yaron Eitan has reported transactions involving Class A Common Stock, including the forfeiture of unvested RSUs and the grant of vested RSUs.

Marpai, Inc. CFO Steve Andrew Johnson acquired 125,000 shares of Class A Common Stock and sold 1,100 shares.

Marpai, Inc. Director Shiv Sagiv has reported transactions involving Class A Common Stock, including the forfeiture of unvested RSUs and the acquisition of vested RSUs.

Marpai, Inc. Director Robert Pons has reported transactions involving Class A Common Stock, including the forfeiture of unvested RSUs and the grant of vested RSUs.

Jennifer Calabrese, a Director at Marpai, Inc., reported transactions involving the forfeiture and vesting of restricted stock units.

Marpai, Inc. CEO Damien Lamendola reports a significant acquisition of Class A Common Stock, increasing his direct and indirect holdings.

Marpai, Inc. is convening its annual stockholder meeting on August 27, 2025, to vote on the election of six directors, the ratification of its independent auditor, and a significant proposal to authorize 2,000,000 shares of blank-check preferred stock.

Marpai, Inc. is holding its annual meeting of stockholders on May 6, 2024, to vote on key proposals including the election of directors, adoption of a stock incentive plan, ratification of the company's auditor, and authorization of preferred stock.

Marpai, Inc. is holding its annual meeting of stockholders on May 6, 2024, to vote on key proposals including the election of directors, adoption of a stock incentive plan, authorization of preferred stock, and approval of an equity line of credit.

Marpai Inc. has filed a registration statement for the resale of up to 5,705,996 shares of its common stock by selling stockholders.

Marpai Inc. has filed a registration statement for the resale of up to 3,943,334 shares of its common stock by selling stockholders, following its delisting from the Nasdaq Capital Market and transition to the OTCQX.

Damien Lamendola and affiliated entities have increased their beneficial ownership in Marpai, Inc. to 40.51% through recent share acquisitions.

Damien Lamendola and affiliated entities, HillCour Investment Fund, LLC and WellEnterprises USA, LLC, have updated their beneficial ownership in Marpai, Inc. to an aggregate of 37.15% of the Class A Common Stock.

Intelligent Fanatics Capital Management and affiliates disclose a 4.4% passive stake in Marpai, Inc. common shares.

Intelligent Fanatics Capital Management LLC and affiliates report a 5.6% beneficial ownership stake in Marpai, Inc. common shares.

Two investment advisers, Tall Pines Capital and Stonebridge Wealth Management, disclosed a combined 3.10% beneficial ownership in MARPAI, INC. common stock.

Tall Pines Capital, LLC and Stonebridge Wealth Management, LLC, through Christopher M. Plahm, have disclosed a combined beneficial ownership of 6.07% of MARPAI, INC.'s common stock.